Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Research & Development (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Research & Development for 11 consecutive years, with $88.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 24.15% to $88.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $388.9 million, a 16.61% decrease, with the full-year FY2025 number at $388.9 million, down 16.61% from a year prior.
  • Research & Development was $88.7 million for Q4 2025 at Intellia Therapeutics, down from $94.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $133.1 million in Q1 2022 to a low of $39.3 million in Q1 2021.
  • A 5-year average of $97.0 million and a median of $98.6 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 238.87% in 2022, then fell 27.03% in 2023.
  • Intellia Therapeutics' Research & Development stood at $71.2 million in 2021, then soared by 40.57% to $100.0 million in 2022, then increased by 8.94% to $109.0 million in 2023, then grew by 7.25% to $116.9 million in 2024, then fell by 24.15% to $88.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Research & Development are $88.7 million (Q4 2025), $94.7 million (Q3 2025), and $97.0 million (Q2 2025).